European Commission grants marketing authorisation for Nepexto® (biosimilar etanercept)

Nepexto® has been approved for use in the EU for all indications of the reference product (Enbrel) – i.e. rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.

Source:

Biospace Inc.